We have located links that may give you full text access.
COMPARATIVE STUDY
ENGLISH ABSTRACT
JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
[Familial hypercholesterolemia and plasma Lp(a) levels: 2 cardiovascular risk factors].
Anales de Medicina Interna : Organo Oficial de la Sociedad Española de Medicina Interna 1999 Februrary
OBJECTIVE: Lipoprotein (a) (Lp(a)) is a modified LDL particle in human plasma. Elevated Lp(a) plasma concentration has been associated with increase risk of premature heart disease in most cross-sectional studies. Familial hypercholesterolemia (FH) is a genetic disorder characterized by an elevation of LDL cholesterol (LDL-C) caused by molecular defects in the LDL receptor gene. The aim of our study is to analyze Lp(a) values in a genetic diagnosed FH group without coronary heart disease (CHD) and explain the considerable variation in clinical severity of FH patients.
METHOD: We have study plasma lipids and lipoprotein levels in 60 subjects with familial hypercholesterolemia without CHD and in 74 normolipidemic controls without personal history of CHD and dyslipidemia of the Valencia area in Spain.
RESULTS: We found differences in total and LDL cholesterol levels and apo B values as expected and also in plasma Lp(a) levels and log transformed values between FH subjects and normolipidemic controls (22.3 mg/dl +/- 19.4 vs 12.5 mg/dl +/- 12.6 p = 0.001 and 1.12 +/- 0.53 vs. 0.84 +/- 0.58 p = 0.008). The percentage of FH subjects with a cut point Lp(a) value > 20 mg/dl is significantly elevated in this group (47% vs 21% p = 0.002). Because of family relationships within the entire study population we also have compared 23 FH probands with the normolipidemic controls. Again the same results have been obtained (Lp(a) levels of 23.21 mg/dl +/- 19.2 vs 12.54 mg/dl +/- 12.63 p = 0.019 and log Lp(a) values of 1.19 +/- 0.42 vs 0.84 +/- 0.58 p = 0.01).
CONCLUSION: Our results indicate that FH subjects will have a more cardiovascular risk due to the potentiation of hypercholesterolemia and elevated Lp(a) values, indicating the addition effects of two different locus implicated in premature coronary heart disease and could explain the considerable variation in clinical severity of FH.
METHOD: We have study plasma lipids and lipoprotein levels in 60 subjects with familial hypercholesterolemia without CHD and in 74 normolipidemic controls without personal history of CHD and dyslipidemia of the Valencia area in Spain.
RESULTS: We found differences in total and LDL cholesterol levels and apo B values as expected and also in plasma Lp(a) levels and log transformed values between FH subjects and normolipidemic controls (22.3 mg/dl +/- 19.4 vs 12.5 mg/dl +/- 12.6 p = 0.001 and 1.12 +/- 0.53 vs. 0.84 +/- 0.58 p = 0.008). The percentage of FH subjects with a cut point Lp(a) value > 20 mg/dl is significantly elevated in this group (47% vs 21% p = 0.002). Because of family relationships within the entire study population we also have compared 23 FH probands with the normolipidemic controls. Again the same results have been obtained (Lp(a) levels of 23.21 mg/dl +/- 19.2 vs 12.54 mg/dl +/- 12.63 p = 0.019 and log Lp(a) values of 1.19 +/- 0.42 vs 0.84 +/- 0.58 p = 0.01).
CONCLUSION: Our results indicate that FH subjects will have a more cardiovascular risk due to the potentiation of hypercholesterolemia and elevated Lp(a) values, indicating the addition effects of two different locus implicated in premature coronary heart disease and could explain the considerable variation in clinical severity of FH.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
Perioperative echocardiographic strain analysis: what anesthesiologists should know.Canadian Journal of Anaesthesia 2024 April 11
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app